1.
Ibrahim AR, Clark RE, Holyoake TL, Byrne J, Shepherd P, Apperley JF, Milojkovic D, Szydlo R, Goldman J, Marin D. Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica [Internet]. 2011Dec.6 [cited 2026Nov.16];96(12):1779-82. Available from: https://haematologica.org/article/view/6149